Overviewing Cleveland Clinic’s International Epilepsy Summit: Imad Najm, MD
August 30th 2024The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the parameters of an upcoming educational event that highlights the current and future role of sEEG in epilepsy surgery. [WATCH TIME: 5 minutes]
Therapeutic Potential of Combination Strategies to Treat Alzheimer Disease: Lloyd Tran, PhD
August 28th 2024The chairman and chief executive officer at Biomed discussed the additive benefits of combination therapy for Alzheimer disease, providing context on the strengths of different drugs and how it might lead to a more precision medicine approach. [WATCH TIME: 6 minutes]
Treatments With Higher Efficacy and Relapses in NMOSD
August 28th 2024This discussion examines how disability accumulation may be influenced by the use of less efficacious treatments, compares the efficacy of novel and traditional NMOSD agents in clinical practice, and reviews relapse rates associated with FDA-approved treatments versus off-label and older therapies.
Raising Awareness for Spinal Muscular Atrophy and Improving Newborn Screening: Crystal Proud, MD
August 27th 2024The director of neurology and neuromuscular medicine at the Children’s Hospital of the King’s Daughters in Norfolk, Virginia, discussed SMA Awareness Month and the enhancements to newborn screening for the disease. [WATCH TIME: 4 minutes]
Development of the DAAE Score for Predicting Progression in Multiple Sclerosis: Tom Fuchs, MD, PhD
August 22nd 2024The postdoctoral researcher at Amsterdam University Medical Center talked about the development of the DAAE score, a tool for predicting the risk of transition to secondary progressive multiple sclerosis. [WATCH TIME: 8 minutes]
Expanding the Potential to Treat Alzheimer Disease With RNA Therapeutics: Sharon Cohen, MD, FRCPC
August 21st 2024The medical director of the Toronto Memory Program at the University of Toronto gave clinical perspective on the promise of mivelsiran, an investigational RNA interference therapeutic, and the idea behind using RNA therapies to treat Alzheimer disease. [WATCH TIME: 5 minutes]
Exploring Cognitive Motor Dissociation in Consciousness Disorders: Nicholas Schiff, MD
August 19th 2024The Jerold B. Katz professor of neurology and neuroscience at Weill Cornell Medicine talked about a recent study that revealed patients who appeared unresponsive to verbal commands in vegetative or minimally conscious states retained high cognitive function. [WATCH TIME: 6 minutes]
Future Directions and Unanswered Questions Regarding S1P Modulator Receptors
August 17th 2024In this episode, Patricia Coyle, MD, FAAN, gave clinical insight on some of the next steps regarding S1P-modulating therapies, including some of the advantages of newer generation agents and the need for future studies to investigate benefits and limitations to each.
Promising Diagnostic Approaches Emerging for Brain Pathologies: James Leverenz, MD
August 16th 2024The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed new diagnostic techniques that show promise for advancing the understanding of brain pathologies like Alzheimer and Lewy Body diseases. [WATCH TIME: 3 minutes]
Overviewing Mechanism of Action of S1P-Modulating Treatments
August 15th 2024In this episode, Patricia Coyle, MD, FAAN, describes the development of S1P modulator receptors, their mechanism of action, potential side effects, and considerations for patient suitability, particularly in comparison to other treatment options like monoclonal antibodies.
Potential of Newer Techniques to Diagnose Dementia with Lewy Bodies: James Leverenz, MD
August 15th 2024The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic talked about challenges of accurately diagnosing dementia with Lewy bodies as well as new methods that show promise in guiding treatment. [WATCH TIME: 3 minutes]